News & Events
Hatchtech's head lice product passes Phase I study
21 / 05 / 2007
DeOvoT, Hatchtech's head louse control product has completed its first human trials finding no side effects or other adverse events associated with the product. 32 patients were treated at escalating dose levels and carefully monitored via observation, blood tests and electrocardiography.…
Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
21 / 05 / 2007
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) notes the publication of new clinical data relevant to the development strategy for Ceflatoninr (homoharringtonine). The paper "Targeted therapy and the T315I mutation in Philadelphia-positive leukemias" by researchers Simona Soverini and…
New Wearable C-PulseTM Driver ready for US Clinical Trial
16 / 05 / 2007
Sunshine Heart, Inc. (ASX: SHC) announced today it had successfully completed the development of the next generation C-PulseTM System for use in the US Feasibility Clinical Trial scheduled to commence in the second half of 2007. The new C-PulseTM system includes a proprietary…
C-PulseTM Pilot Clinical Trial Abstract accepted by CSANZ
10 / 05 / 2007
Sunshine Heart, Inc (ASX: SHC) announced today that an abstract of the C-PulseTM Pilot Clinical Trial has been reviewed and accepted by the Abstract Grading Subcommittee of the Cardiac Society of Australia and New Zealand (CSANZ) Council. Entitled "First-in-human study of a…
Sunshine Heart Completes Training for US Feasibility Trial
03 / 05 / 2007
Sunshine Heart, Inc. (ASX: SHC) announced today the completion of training of clinicians and other healthcare professionals at the six US medical centres scheduled to participate in the US Feasibility Clinical Trial of the company''s C-PulseT heart assist device. The training…
ChemGenex Reports Preclinical Data at American Association of Cancer Research (AACR) Annual Conference
17 / 04 / 2007
ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today the presentation of new preclinical data on its lead compound, Ceflatoninr (homoharringtonine, or HHT), demonstrating its oral bioavailability and further describing the drug's mechanism of action. Ceflatonin is…
ChemGenex Announces Initiation of Second Phase 2/3 Clinical Trial for Ceflatoninr in CML
04 / 04 / 2007
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today that it has treated the first patient in a new phase 2/3 clinical study (CML-203) designed to evaluate the efficacy of Ceflatoninr (homoharringtonine or HHT) in patients with chronic myeloid leukemia (CML) who have failed or…
ChemGenex Announces the Completion of A$21 Million Financing
03 / 04 / 2007
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today the completion of an A$10.5 million capital raising achieved by a non-renounceable rights issue for 16,891,916 new ChemGenex shares and associated options. The successful rights issue follows the raising of A$10.5 million by…
Sunshine Heart appoints CRO for US clinical trial: Alquest, Inc.
29 / 03 / 2007
Sunshine Heart (ASX: SHC) has appointed US clinical experts, Alquest Inc, to fast track the commencement of the multi-centre feasibility trial of the C-PulseT implantable heart assist device in North America. Alquest is an internationally respected Contract Research…
Appointment of New Chief Financial Officer
22 / 03 / 2007
Sunshine Heart (ASX:SHC) today announced the appointment of Mr Brian H Bolton BCom, MBA, FCPA as Chief Financial Officer and Company Secretary effective 16 April 2007. Mr Bolton joins the Company's senior management and will provide support to the CEO and Board on…
Peptech appoints global financial adviser to examine strategic options
14 / 03 / 2007
Australian biotechnology company, Peptech Limited (ASX: PTD; AIM: PTDx) today announced the appointment of Citigroup Corporate and Investment Banking to advise the company on a broad range of strategic investment opportunities designed to unlock the inherent value in its business. …
Phenomix Completes $55 Million Series C Financing
08 / 03 / 2007
Phenomix Corporation, a drug discovery and development company, announced today the closing of a $55 million private placement of its Series C preferred stock. New investor Nomura Phase4 Ventures led the financing. Existing investors JP Morgan Partners, Delphi Ventures, Baker Brothers,…
Phenomix Completes Phase 2A Clinical Trial - - Diabetes Drug is Efficacious and well Tolerated
02 / 03 / 2007
Phenomix Corporation, a drug discovery and development company, announced today the completion of a multinational phase 2a clinical trial of PHX1149, a novel orally administered inhibitor of DPP4 for the treatment of type 2 diabetes mellitus. Statistical analysis of the trial data shows…
Heart failure experts appointed as Co-Principal Investigators for Sunshine Heart's
22 / 02 / 2007
Sunshine Heart (ASX: SHC) is pleased to announce that Dr William T Abraham of Ohio State University, Columbus, Ohio and Dr Patrick M McCarthy of Northwestern University, Chicago, Illinois have agreed to become the Co-Principal Investigators for the C-PulseT Feasibility Trial in the…
CoDa Therapeutics Secures $10.0 Million in Additional Series A Financing
21 / 02 / 2007
Wound Healing Drug Development Company Will Use Funds to Achieve Clinical Development Milestones CoDa Therapeutics, Inc., today announced a second closing of its Series A financing, receiving $10.0 million in additional venture capital commitments…
Anticancer company Proacta raises a further US$35m and extends
08 / 02 / 2007
Proacta Inc, an oncology drug discovery and development company, announced today that it has raised a further US$35m in a Series B round of funding. This new funding will be used to take New Zealand-discovered anticancer compound PR-104 through the next phase of clinical…
Proacta Inc Completes $35M Series B Financing
07 / 02 / 2007
Capital will Fund Additional Clinical Studies Targeting Hypoxic Tumors and Expand US Team Proacta Inc, a clinical stage biotechnology company, today announced the completion of a $35M Series B financing. The new funding will take Proacta's lead compound,…
CogState Signs its First Agreement with Abbott
05 / 02 / 2007
Key points: - CogState technology to be used for the first time by Abbott in a clinical trial - CogState's contracted future revenue exceeds A$2.1m - Abbott is a global healthcare company CogState Ltd (ASX:CGS) announced today that it has…
Antipodean Pharmaceuticals Initiates Phase 2 Trial in Hepatitis C
05 / 02 / 2007
Potential Additional Treatment Strategy to Reduce Liver Damage in Chronic Patients Antipodean Pharmaceuticals, Inc. today announced it has initiated a Phase 2 clinical trial of its lead compound MitoQ (mitoquinone) to investigate the drug's efficacy to reduce…
Phase III Bronchitol Clinical Trial Fully Recruited
02 / 02 / 2007
Pharmaceutical company Pharmaxis (ASX: PXS, NASDAQ: PXSL) today announced that its Phase III clinical trial of Bronchitol in bronchiectasis has reached the recruitment target of 354 subjects. The double blinded placebo controlled trial, which commenced dosing subjects in May…
Portland Orthopaedics' Equator Plus Cup Launched in US
15 / 01 / 2007
First Implant of Portland's third product offering in Oregon, US Portland Orthopaedics Limited (ASX:PLD) first series of Equator Plus Cups have been implanted in Portland, Oregon today. The Equator Plus will be the third product Portland has available in the USA and is…
Peptech realises A$178m with Domantis sale completion
08 / 01 / 2007
Key Points - GSK's acquisition of Domantis completed - Peptech share of gross proceeds is GBP 71.3 million (approximately A$178 million or $1.08 per share) - Peptech realises a A$138.2 million gain from an investment of A$40.2 million -…
Sunshine Heart on track for US trial following Pre-IDE Meeting with FDA
22 / 12 / 2006
Key points Sunshine Heart achieved a significant milestone with a successful FDA meeting. C-PulseTM was presented to the FDA by leading US and Australian clinicians FDA provided positive feedback for the C-PulseT product and clinical focus …
Peptech to use UK listing to drive growth strategy
20 / 11 / 2006
Australian biotechnology company Peptech Limited (ASX:PTD) ("Peptech" or the "Company") today announced in London it is preparing to list on AIM, a market regulated by the London Stock Exchange. Peptech's Chief Executive Officer Dr John Chiplin said that the listing…
Sunshine Heart Completes First Tranche of $20 million Institutional Capital Raising
14 / 11 / 2006
Sunshine Heart today advised that it has now received $13.8 million from investors. This represents the first tranche of the $20 million institutional Capital Raising approved by shareholders at the Extraordinary General Meeting held on 20 October 2006. Consequently the…